

November 9th-12th



TABLE OF CONTENTS

Welcome from the Committee.....	1
Acknowledgements.....	2
<hr/>	
Keynote Address	3
Program Overview.....	4
<hr/>	
Detailed Program Information	
GPEN2016 Welcome, Keynote Address and Reception.....	7
Social Event	7
Banquet.....	8
Awards Ceremony.....	8
Thursday Scientific Schedule.....	9
Friday Scientific Schedule.....	11
Saturday Scientific Schedule.....	13
Poster Presentations.....	17
<hr/>	
Transportation and Contact Information.....	22
Sponsors.....	23
Participant List.....	31
Welcome from GPEN2018: Singapore.....	38

WELCOME FROM THE COMMITTEE

Dear GPEN2016 Attendees,

We are excited to welcome you to the 11th biennial meeting of the Globalization of Pharmaceutics Education Network (GPEN). GPEN was founded here in Lawrence, Kansas in 1996, and it is with great pride that we may host you again on our 20th anniversary! At our first meeting, we hosted 11 universities and 31 graduate students and postdoctoral fellows. Twenty years later, GPEN2016 welcomes 286 participants from its 49 member universities and 41 “observers” from its sponsors to continue our traditions of fostering scientific, professional, and personal exchange on a global stage.

The venues for the GPEN2016 events are located both in historic downtown Lawrence as well as at the University of Kansas. A social event will allow participants to enjoy BBQ on an authentic Kansas buffalo ranch. The banquet will be held in an historic building that was originally established as a barbed wire manufacturing company in the 1880’s.

Graduate students and postdoctoral fellows will share their research in 49 podium presentations and 106 posters at the Lawrence Arts Center. At the School of Pharmacy on KU’s West Campus, faculty and industrial representatives will share their expertise in seven diverse and relevant short courses.

GPEN2016 will also have a special focus on entrepreneurship. We look forward to the keynote lecture by Dr. Mike Powell of Sofinnova Ventures entitled “Drug Discovery and Development: The Venture Capital Perspective.” Participants will also have the chance to tour the Bioscience and Technology Business Center (BTBC). The BTBC is an invaluable, growing resource located along KU’s West Campus, and provides space and guidance for large companies and start-ups alike.

The Organizing Committee sincerely wishes you a productive and pleasant meeting. We hope you can make the most of the scientific sessions, the career center and networking opportunities, and the history-centered social events that showcase Lawrence. Details of the conference including the schedule, abstracts, and transportation between the different conference venues can all be found on our website: gpenconference.com. Please do not hesitate to ask a member of the GPEN2016 Organizing Committee if you need any help!

On behalf of the Organizing Committee,

Michaela McNiff, Lorena Antúnez Napolitano, and Samantha Pace
Student Chairs

Sanjeev Agarwal, Matthew Christopher, Laura Drbohlav, Indira Prajapati, Melissa Pressnall, and Vishal Toprani
Student Members

Dr. Jeffrey Krise
Faculty Chair

ACKNOWLEDGEMENTS

The GPEN2016 Organizing Committee would like to thank the KU School of Pharmacy for providing GPEN with access to the School of Pharmacy Building on KU's West Campus for the GPEN2016 Short Courses and for providing funding to rent the Lawrence Arts Center for the GPEN2016 Podium and Poster Sessions.

The Organizing Committee also thanks the following sponsors for contributing toward the housing and registration fees for GPEN-sponsored participants: Absorption Systems LP; AstraZeneca; Bristol-Myers Squibb Co.; Elsevier; Forum for Pharmaceutical Technology Innovation, Japan; Genentech, Inc.; Ligand Pharmaceuticals; Eli Lilly and Company; Merck; The Nagai Foundation Tokyo; Novo Nordisk A/S; Promius Pharma, LLC; Sanofi; Silvergate Pharmaceuticals, Inc.; and Teikoku Seiyaku Co. Ltd.

The Organizing Committee is exceedingly grateful to all those who have provided support and guidance while organizing the GPEN2016 meeting. We would especially like to thank:

- ❖ GPEN Founder and Treasurer Ronald Borchardt, the GPEN Board of Directors (Kenneth Audus, Teruna Siahaan, and Per Artursson) and the GPEN Executive Committee members (Patrick Augustijns, Christian Schöneich, Peter Swaan, Yoshi Takakura, Joseph Nicolazzo, and Jay Sisco)
- ❖ Ms. Nancy Helm (University of Kansas), who was instrumental in the day-to-day organizing and planning of the meeting
- ❖ Keynote speaker Dr. Mike Powell (Sofinnova Ventures)
- ❖ All GPEN2016 sponsors
- ❖ All judges of oral and poster presentations
- ❖ All industry observers
- ❖ All short course coordinators
- ❖ All session chairs
- ❖ All faculty and industrial short course speakers
- ❖ All career center participants
- ❖ The GPEN2014 Organizing Committee, particularly Bjorn Peters

KEYNOTE ADDRESS

Mike Powell, PhD

General Partner

Sofinnova Ventures

“Drug Discovery and Development: The Venture Capital Perspective”



Dr. Powell is a General Partner at Sofinnova Ventures, Inc. He joined Sofinnova in 1997 as a member of the life science investment team and has focused on clinical-stage product companies, particularly in the oncology and neurology areas. Dr. Powell has 32 years of experience, including 15 years of R&D before venture. Dr. Powell has been involved in more than 50 clinical programs, and is the author of 90 publications and books, including a 1,000-page treatise on vaccine design. He was the initial venture investor of: Actelion (ATLN), Intermune (ITMN), Orexigen (OREX), Seattle Genetics (SGEN), Threshold (THLD), and Trius (TSRX) and other public and private companies such as Intellikine (sold to Millennium-Takeda), Mirna and Labrys Biologics (sold to Teva).

Mike was the first person in the biotech industry to be honored by the American Association of Pharmaceutical Scientists as an AAPS Fellow. He has also served on the journal editorial boards of *Journal of Pharmaceutical Sciences* and the *Journal of Controlled Release*. He has been the Board President of the AIDS Vaccine Advocacy Coalition, as well as advisor to the Institute for One World Health, IAVI (International AIDS Vaccine Initiative), and the Bill and Melinda Gates Foundation. Mike is also Adjunct Associate Professor in the Department of Pharmaceutical Chemistry at the University of Kansas, one of the top US pharmacy schools. Before joining Sofinnova, he was group leader of drug delivery at Genentech. During his tenure there, he and colleagues spun off VaxGen, an AIDS vaccine company. Prior to Genentech, he helped start Cytel as the Director of Product Development. Before this he was Senior Scientist and Project Team Leader at Syntex Research.

Mike received his PhD in Chemistry from the University of Toronto and carried out postdoctoral studies in bio-organic chemistry at the University of California as a National Science and Engineering Research Council Scholar. Mike and his wife Tana live in San Francisco, and they enjoy flying, skiing, diving and fly fishing.

PROGRAM OVERVIEW

Wednesday, November 9, 2016

Time	Location	Event
12:00 pm–4:30 pm	Eldridge Hotel	Conference Registration
5:00 pm–5:30 pm	Liberty Hall	Opening Remarks and Welcome
5:30 pm–6:30 pm	Liberty Hall	Keynote Lecture Mike Powell, PhD
6:30 pm–8:00 pm	Eldridge Hotel	Welcome Reception
8:00 pm	Eldridge Hotel	Bus Service to the Best Western and Double Tree Hotels

Thursday, November 10, 2016

Time	Location	Event
8:00 am–9:40 am	Lawrence Arts Center	Podium Presentations I: Drug Delivery
9:40 am–10:40 am	Lawrence Arts Center	Coffee Break, Poster Session I
10:40 am–12:00 pm	Lawrence Arts Center	Podium Presentations II: Drug Delivery
12:00 pm–1:10 pm	Maceli's Banquet Hall	Lunch
1:15 pm–1:20 pm	Lawrence Arts Center	Welcome from the LAC
1:20 pm–2:20 pm	Lawrence Arts Center	Podium Presentations III: Biotechnology
2:20 pm–3:20 pm	Lawrence Arts Center	Coffee Break, Poster Session II
3:20 pm–4:20 pm	Lawrence Arts Center	Podium Presentations IV: Biotechnology
4:20 pm–5:45 pm		Free Time <i>Buses to Double Tree and Best Western Hotels will depart from the LAC at 4:20 pm</i>
5:45 pm	Lawrence Arts Center Double Tree Hotel Best Western Hotel	Buses to Circle S Ranch leaving from Lawrence Arts Center and from Double Tree and Best Western Hotels
6:15 pm–9:30 pm	Circle S Ranch	BBQ and Bonfire at a Kansas Buffalo Ranch
8:30 pm–9:30 pm	Circle S Ranch	Bus Service to Lawrence Arts Center and Double Tree and Best Western Hotels

Friday, November 11, 2016

Time	Location	Event
8:00 am–9:40 am	Lawrence Arts Center	Podium Presentations I: Drug Delivery and Pharmacokinetics
9:40 am–10:40 am	Lawrence Arts Center	Coffee Break, Poster Session I
10:40 am–12:00 pm	Lawrence Arts Center	Podium Presentations II: Drug Delivery and Pharmacokinetics
12:00 pm–1:10 pm	Maceli's Banquet Hall	Lunch
1:10 pm–3:10 pm	Lawrence Arts Center	Podium Presentations III: Pharmaceutics/Pharmaceutical Technology
3:10 pm–4:10 pm	Lawrence Arts Center	Coffee Break, Poster Session II
4:10 pm–5:10 pm	Lawrence Arts Center	Podium Presentations IV: Pharmaceutics/Pharmaceutical Technology
5:10 pm–6:15 pm		Free Time <i>Buses to Double Tree and Best Western Hotels will depart from the LAC at 5:10 pm</i>
6:15 pm–9:00 pm	Abe and Jake's Landing	Conference Banquet <i>Buses will pick up those participants staying at the Double Tree and Best Western Hotels at 6 pm.</i>
9:00 pm	Abe and Jake's Landing	Bus service to Double Tree and Best Western Hotels

Saturday, November 12, 2016

Time	Location	Event
8:30 am–12:10 pm	KU School of Pharmacy Room #2040	Short Course I Mechanistic Determinants of the Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins
8:30 am–12:10 pm	KU School of Pharmacy Room #3002	Short Course II Cell Culture Systems in Pharmacokinetics Research- Proven & Promising
8:30 am–12:10 pm	KU School of Pharmacy Room #3005	Short Course III Entrepreneurship
8:30 am–12:10 pm	KU School of Pharmacy Room #3020	Short Course IV Challenges of Stabilizing Therapeutic Proteins
8:30 am–12:10 pm	KU School of Pharmacy Room #1020	Short Course V Case Studies in Vaccine Development
8:30 am–12:10 pm	KU School of Pharmacy Room #2020	Short Course VI Lymphatic Drug Delivery Systems & Modulating Immune Response
8:30 am–12:10 pm	KU School of Pharmacy Room #3004	Short Course VII Strategies in Solid Form Design: From Amorphous Materials to Particle and Crystal Engineering
10:00 am–10:20 am	KU School of Pharmacy Level 2 Atrium	Coffee Break
12:10 pm–1:30 pm	Bioscience and Technology Business Center	Lunch <i>Self-guided tours of the facility are encouraged</i>
1:30 pm–2:30 pm	KU School of Pharmacy Room #2020	Award Ceremony and Conference Closing
2:30 pm	KU School of Pharmacy	Final buses to Kansas City Airport

DETAILED PROGRAM INFORMATION

Welcome and Keynote Address

Wednesday, November 9th, 5:00 pm–6:30 pm

Sponsored by KU Innovation and Collaboration

Location: Liberty Hall, 644 Massachusetts St.

The Provost of The University of Kansas, Neeli Bendapudi, will welcome participants to Lawrence. Professor Ken Audus, as chairman of GPEN, will welcome participants and provide information about the history of GPEN. Steve Jansen, a local Lawrence historian, will provide you with a brief history of Lawrence and some of the historical venues used during the GPEN2016 conference. Mike Powell will then deliver the Keynote address “Drug Discovery and Development: The Venture Capital Perspective”.

Opening Reception

Wednesday, November 9th, 6:30 pm–8:00 pm

Sponsored by City of Lawrence

Location: Eldridge Hotel, 701 Massachusetts St.

Please join us at the Opening Reception following the Keynote Address. The reception will feature hors d'oeuvres and beer and wine and will take place at the Eldridge Hotel, which is just across the street from Liberty Hall.

BBQ and Bonfire at a Kansas Buffalo Ranch

Thursday, November 10th, 5:45 pm–8:30 pm

Sponsored by Ronald T. and Pamela K. Borchardt and Dhiren and Kailas Thakker

Established in 1862, the Circle S Ranch has been a working ranch for 6 generations and features tall native prairie grass, buffalo and longhorn cattle. The buses will leave Lawrence from the Lawrence Arts Center and Double Tree and Best Western Hotels at 5:45pm.



Conference Banquet

Friday, November 11th, 6:15 pm–9:00 pm

Sponsored by KU Department of Pharmaceutical Chemistry

Buses from Best Western and Double Tree Hotels will pick up participants at 6pm from their hotel. All others should walk to the facility, which is located on 8 E 6th Street (see gpenconference.com for directions).

Abe & Jake's Landing originally began as the Consolidated Barbed Wire Company in the late 1880's. Abe and Jake's Landing takes its name from Abe Burns and Jake Washington, two local fisherman who had a fishing cabin next to the barbed wire building.



Awards Ceremony

Saturday, November 12th, 1:30 pm–2:30 pm

Sponsored by Sofinnova Ventures

Location: #2020 School of Pharmacy

Student poster and podium presentations will be individually judged by two faculty members. The top three student presenters in the poster and podium categories will be recognized and awarded.

Judges should have received their evaluation forms at registration and should return them to the organizing committee at the registration table immediately following each podium or poster session.

THURSDAY SCIENTIFIC SCHEDULE

Thursday, November 10, 2016

Location: Lawrence Arts Center

Podium Session I, Drug Delivery and Pharmacokinetics: *Sponsored by Abbvie*

Code	Time	Author	Title
S1	8:00 am	Buddhadev Layek	Glycoengineered Mesenchymal Stem Cells as an Enabling Platform for Two-step Targeting of Solid Tumors
S2	8:20 am	Jan-Jaap Verhoef	Nature's Nanoparticles and Its Slow-release Mechanism
S3	8:40 am	Aaron Dolor	Disrupting the Tumor Matrix for Increased Nanoparticle Drug Penetration
S4	9:00 am	Peng Zhao	iTEP Nanoparticle-delivered Salinomycin Displays an Enhanced Antitumor and Anti-Metastasis Efficacy in Orthotopic Breast Tumors
S5	9:20 am	Morgan Giles	Efficient Aqueous Remote Loading of Leuprolide in PLGA Microspheres

9:40 am –10:40 am Coffee Break and Poster Session I

Sponsored by F. Hoffmann-La Roche AG

SESSION II, Drug Delivery and Pharmacokinetics: *Sponsored by Abbvie*

Code	Time	Author	Title
S6	10:40 am	Shashank Pinnapireddy	Photo-enhanced Gene Delivery Using Curcumin Embedded Composite Lipopolyplexes
S7	11:00 am	Adem Sahin	Comparing Intracellular Delivery of PLGA and Chitosan Nanoparticles: Lessons and Challenges
S8	11:20 am	Yu Wan	Development of a Stearylated Peptide for Delivering siRNA into Mammalian Cells
S9	11:40 am	Sasi Bhushan Yarragudi	Biodegradable, Mucoadhesive Microparticles of Tamarind Seed Polysaccharide for Enhanced Olfactory Deposition

12:00 pm –1:20 pm Lunch at Maceli's Banquet Hall

Sponsored by Allergan, Plc.

SESSION III, Biotechnology: *Sponsored by Gilead Sciences, Inc.*

Code	Time	Author	Title
S10	1:20 pm	Ryan Lillico	Epigenetic Enzyme Inhibitors Induce Global Changes in Histone Post-translational Modifications
S11	1:40 pm	Aniv Mann	'Into the Wild'- Cerebral Folate Uptake Mechanisms in Epilepsy
S12	2:00 pm	Khalid Al-Kinani	The Effect of Core Fucosylation on Human IgG2 Structure and Function

2:20 pm –3:20 pm Coffee Break and Poster Session II

Sponsored by Pfizer, Inc.

SESSION IV, Biotechnology: *Sponsored by Gilead Sciences, Inc.*

Code	Time	Author	Title
S13	3:20 pm	Aditya Gandhi	Physical Stability of Antibody-Drug Conjugates
S14	3:40 pm	Sou Tanoue	Analysis of Catalytic Property of Human Esterase D, S-Formylglutathione Hydrolase, and Its Polymorphic Enzyme
S15	4:00 pm	Nantaporn Namviriyachote	Polyurethane Foam Dressing with Natural Polyols and Silver: Physio-chemical, Mechanical and Antibacterial Properties

FRIDAY SCIENTIFIC SCHEDULE

Friday, November 11th, 2016

Location: Lawrence Arts Center

Podium Session I, Drug Delivery and Pharmacokinetics: *Sponsored by Pfizer, Inc.*

Code	Time	Author	Title
S16	8:00 am	Thu Pham	Design and Characterization of Antihistamine Loaded Orally Dissolving Films as a Potential New Dosage Form
S17	8:20 am	Igor Chekhtman	Mechanism of Drug Release from Levofloxacin-monomer Conjugates
S18	8:40 am	Elodie Millart	Lipid-based Janus Nanoparticles: Overview and Focus on Ferrofluid Incorporation for Theranostic Applications
S19	9:00 am	Andrea Treyer	Phospholipid Content is a Major Determinant of Intracellular Binding of Drugs

9:40 am –10:40 am Coffee Break and Poster Session I

Sponsored by Eli Lilly and Company

Podium Session II, Drug Delivery and Pharmacokinetics: *Sponsored by Pfizer, Inc.*

Code	Time	Author	Title
S21	10:40 am	Nico Setiawan	What is the True Driving Force for Drug Absorption in the Presence of Solubilizing Excipients?
S22	11:00 am	Anna-Kaisa Rimpela	Drug Distribution to Retinal Pigment Epithelium: Studies on Melanin Binding, Cellular Kinetics and SPECT/CT Imaging
S23	11:20 am	Laura Pelkonen	Drug Interactions with Isolated Retinal Pigment Epithelium Melanin
S24	11:40 am	Diachi Fujita	Involvement of Intestinal Transporter OATP2B1 in Gastrointestinal Toxicity Induced by SN-38, an Active Metabolite of Anticancer Irinotecan

12:00 pm –1:10 pm Lunch at Maceli's Banquet Hall

Sponsored by Boehringer-Ingelheim Pharmaceuticals, Inc.

Podium Session III, Pharmaceuticals/Pharmaceutical Technology: *Sponsored by Allergan, Plc.*

Code	Time	Author	Title
S25	1:10 pm	Tahnee Dening	Development of Clay-Lipid Hybrid Microparticles for the Improved Oral Delivery of Poorly Water-Soluble Drugs
S26	1:30 pm	Katerina Simkova	On Production of Fast-dissolving Low-density Powders for Deep Lung Deposition by Spray Drying of a Nanosuspension
S27	1:50 pm	Monica Lavan	Cysteine 34 Mono-PEGylated Human Serum Albumin for the Solubilization and Delivery of Chemotherapeutics
S28	2:10 pm	Arushi Manchanda	Sensitivity of the Calculated Value of the Amorphous Solubility Enhancement Ratio on Experimental Conditions Used to Determine Input Parameters
S29	2:30 pm	Xian Weng-Jiang	Aqueous In-flow Coprecipitation Synthesis of USPIO as T1 Enhancing MR Contrast Agent
S30	2:50 pm	Su Min Han	The Effect of Tween 80 on Particle Size of PTX Loaded Liposome

3:10 pm –4:10 pm Coffee Break and Poster Session II

Sponsored by Eli Lilly and Company

Podium Session IV, Pharmaceuticals/Pharmaceutical Technology: *Sponsored by Allergan, Plc.*

Code	Time	Author	Title
S31	4:10 pm	Tiziana Di Francesco	Maltofer® vS. Iron Polymaltose Similar: Could We Spot Differences?
S32	4:30 pm	Jaya Mishra	Use of Spray Drying as a Method for Formation of Co-amorphous Drug-amino-acid Mixtures
S33	4:50 pm	Amelia Deitchman	Maximizing the Use of Currently Available Antibiotic Therapies: Tetracycline Augments Tigecycline's Spectrum of Activity

SATURDAY SCIENTIFIC SCHEDULE

Saturday, November 12, 2016

Location: KU School of Pharmacy Building

Short Courses

Short Courses are sponsored by American Association of Pharmaceutical Scientists, Amgen, Inc., Cardinal Health Regulatory Sciences, Celgene Corporation, Eli Lilly and Company, and Pfizer, Inc.

Short Course I: Mechanistic Determinants of the PK and PD of Therapeutic Proteins

Location: Room #2040

Code	Time	Author	Title
S34	8:30 am	Joseph Balthasar	Introduction to Primary Determinants of Protein Pharmacokinetics
S35	9:05 am	Yutaro Hoshi (Student)	Quantitative Phosphoproteomics for the Regulatory Mechanism of Blood-brain Barrier P-glycoprotein: Oxidative Stress-induced Activation of Abl and Src Kinases Enhanced P-glycoprotein Internalization
S36	9:25 am	Donald Mager	Target Mediated Disposition of Biological Drugs
	10:00 am	Coffee Break	
S37	10:20 am	Jarod Waybright (Student)	A Chemical Biology Approach to Phosphatidylinositide Metabolic Analysis
S38	10:40 am	Joseph Balthasar	Physiologically-based Pharmacokinetic Modeling to Predict the Disposition of Monoclonal Antibodies
S39	11:15 am	Dhavalkumar Shah	Use of Mechanistic Models to Predict the Pharmacokinetics and Pharmacodynamics of Antibody-drug Conjugates
S40	11:50 am	Peter Tiefenbock (Student)	A Novel Cell Engineering Platform Based on Microinjection of Enzyme-loaded Liposomes

Short Course II: Cell Culture Systems in Pharmacokinetics Research – Proven & Promising

Location: Room #3002

Code	Time	Author	Title
S41	8:30 am	Ismael Hidalgo	Cell Culture Systems Validation and Strategy to Monitor Cell Culture Uniformity
S42	9:05 am	Cen Guo (Student)	Is it Necessary to Measure Intracellular Unbound Fraction of Inhibitors to Predict Hepatic Efflux Transporter-mediated Drug Interactions?
S43	9:25 am	Teruna Siahaan	Delivering Molecules Through The BBB Intercellular Junctions
	10:00 am	Coffee Break	
S44	10:20 am	William D. Hedrich (Student)	Targeting the Constitutive Androstane Receptor as a Novel Method for Treating Hematologic Malignancies
S45	10:40 am	Sabeth Verpoorte	Organs-on-a-Chip: The Quest for Biological Insight
S46	11:15 am	Michael Zhuo Wang	Exosomal Drug-Metabolizing Enzymes: Myth or Truth
S47	11:50 am	Jari Rubbens (Student)	Gastric and Duodenal Ethanol Concentrations in Healthy Volunteers Following Intake of Alcoholic Beverages

Short Course III: Entrepreneurship

Patrick Dentinger (Absorption Systems), Cory Berkland (University of Kansas), Fred Meyer (The University of Kansas Cancer Center), and GR Underwood (Bioscience & Technology Business Center) will lead an interactive discussion on entrepreneurship.

Location: Room #3005

Time	Topic
8:30 am	Opening remarks and panel member introduction
8:50 am	<ul style="list-style-type: none">• Outline of session• Business opportunity presented• Short video "9 Steps to Business Model Generation" will be shown• Participants divided into 3 groups
9:00 am	Groups meet separately to discuss steps in business model generation
10:00 am	Coffee Break
10:20 am	Panel members discuss what really happened and introduce Phase 2
10:30 am	Groups meet separately to discuss Phase 2
11:00 am	Groups reconvene and present their findings
11:30 am	Open discussion

Short Course IV: Challenges of Stabilizing Therapeutic Proteins

Location: Room #3020

Code	Time	Author	Title
S48	8:30 am	Thomas Tolbert	Effects of Glycosylation on Stabilization of Proteins and Assessment of Biological Activity
S49	9:05 am	Atsushi Hamana (Student)	Sustained Expression System of Interferon-beta by Using Interferon-inducible Mx Promoter for Interferon-beta Gene Therapy
S50	9:25 am	Christian Schöneich	Novel Degradation Pathways of Proteins with Impact on Formulation Stability and Immunogenicity
	10:00 am	Coffee Break	
S51	10:20 am	Zhe Li (Student)	Thermo-responsive Protein Switch that Modulates Epidermal Growth Factor Receptor Activity
S52	10:40 am	John Stobaugh	Implementation of an Xtreme Ultra Pressure Chromatographic System (XUPLC) for the Analysis of Protein Degradation Products
S53	11:15 am	Mike Pikal	Formulation of Proteins for Stabilization by Freeze Drying
S54	11:50 am	Laura Weber (Student)	Development of a Dentotropic Enzyme-based Antimicrobial System for Caries Prevention and Treatment

Short Course V: Case Studies in Vaccine Development

Location: Room #1020

Code	Time	Author	Title
S73	8:30 am	David Volkin	Characterizing and Formulating Vaccines as Well-defined Pharmaceutical Dosage Forms: Challenges and Opportunities
S75	9:15 am	Russ Middaugh	Development of a Vaccine for Ricin
	10:00 am	Coffee Break	
S76	10:20 am	Mara Leone (Student)	High Protein Content in Dissolvable Microneedles for Dermal Vaccine Delivery
S77	10:40 am	Bill Picking	Vaccines and Antigen Design
S78	11:15 am	Wendy Picking	Toward a <i>Shigella</i> vaccine. DBF, a Broadly Protective Protein Antigen Vaccine Against Shigellosis
S79	11:50 am	Jeong Uk Choi (Student)	Enhancing Tumor Blood Perfusion Using Orally Active Heparin to Increase the Distribution of Anti-cancer Therapeutics Inside the Tumor Tissue

Short Course VI: Lymphatic Drug Delivery Systems & Modulating Immune Response

Location: Room #2020

Code	Time	Author	Title
S55	8:30 am	Cory Berkland	Soluble Antigen Arrays as Antigen-specific Autoimmune Therapy
S56	9:05 am	Yan Liu (Student)	Pharmacological Evaluation of Novel Combination Inhalation Agents for COPD
S57	9:25 am	Laird Forrest	Particle Therapy in the Treatment of Lymphatic Cancers
	10:00 am	Coffee Break	
S58	10:20 am	Lisa Nothnagel (Student)	DoE-based Development and Release Testing of TMP-001-loaded Nanoparticles
S59	10:40 am	Davide Brambilla	Drug Delivery Tools for the Functional Monitoring of the Lymphatic System
S60	11:15 am	Gerrit Borchard	Nanocarriers for DNA Vaccination Against <i>M. tuberculosis</i>
S61	11:50 am	Jake Kraft (Student)	Novel Lipid-nanoparticles for In Vivo Near-infrared and Magnetic Resonance Imaging Elucidate Nanoparticle-bound Small Molecule Distribution in Lymph vs Blood

Short Course VII: Strategies in Solid Form Design: From Amorphous Materials to Particle and Crystal Engineering

Location: Room #3004

Code	Time	Author	Title
S66	8:30 am	Michael Hageman	Enhanced Oral Exposure Through Solid Form Control in Discovery
S67	9:05 am	Parthiban Anbalagan (Student)	Tablet Compression Tooling Design Modifications to Optimize Tablet Properties
S68	9:25 am	Christel Bergström	Computational Methods to Explore the Success of Amorphous Solids to Enhance Dissolution and Supersaturation
	10:00 am	Coffee Break	
S69	10:20 am	Rattavut Teerakapibal (Student)	Formation of Liquid-crystalline Structures in Amorphous Drugs
S70	10:40 am	Nair Rodriguez-Hornedo	Understanding and Design of Co-crystals as an Alternate Solid Form Strategy
S71	11:15 am	Rao Mantri	API Solid Form Selection, Crystallization & Particle Engineering to Enable Formulation Development
S72	11:50 am	Carolyn Thum (Student)	Magnetite Loaded PLGA NPs as a Powerful Combination for Drug Delivery Purposes

POSTER PRESENTATIONS

Thursday, November 10th 9:40 am–10:40 am

P1	Pre-formulation Characterization of Three Non-replicating Rotavirus Vaccine Recombinant Protein Antigens (P2-VP8-P[4], P2-VP8-P[6] and P2-VP8-P[8]) Produced in E. Coli Sanjeev Agarwal (University of Kansas)
P3	Separation of Dynorphin Peptides by Capillary and Microchip Electrophoresis with Laser Induced Fluorescence Detection Abdullah Al-Hossaini (University of Kansas)
P5	Physicochemical Properties of Traditional Adjuvants Promote Different Mechanisms of Phospholipid Reorganization and Dendritic Cell Activation Lorena Antunez (University of Kansas)
P7	Influence of Water Intake on the Intraluminal Behavior and Systemic Exposure in Humans for a Cyclodextrin-based Formulation of Itraconazole Philippe Berben (KU Leuven)
P9	Identification of D-amino Acids in Light-exposed Monoclonal Antibody Formulations. Rupesh Bommana (University of Kansas)
P11	Targeting Intestinal Lymphatic Lymphocytes: A potential Route to Treat Immune-metabolic Diseases Enyuan Cao (Universidade de São Paulo)
P25	Biophysical Analysis of the Pore Size and Pore Densities of Caco-2 and MDCK Cell Monolayers Using a Model Modulator Mei Feng (University of Kansas)
P27	The Selection of Highly Stable Aptamers Selected from a 2'- fully modified fGmH RNA Library Adam Friedman (University of North Carolina at Chapel Hill)
P29	Inhibiting the Lysosomal V-ATPase Decreases Intracellular Hydrochloride Crystal Formation by a Weakly Basic Poorly Soluble Drug Tehetina Woldemichael (University of Michigan)
P31	Multivalent Antigen Arrays Leverage Antigen-Specific Binding and Signaling Modulation in B Cells to Regulate Autoimmune Response Brittany Hartwell (University of Kansas)
P33	A Study on the Effects of Excipient Shielding on the Intrinsic Dissolution Rate of Acetylsalicylic Acid Tze Ning Hiew (National University of Singapore)
P45	Spray-dried Vaccine Particles for Photochemical Internalization Sarah Kindgen (ETH Zurich)
P47	Development of Methods to Localize Peptides and Proteins in Different Brain Regions Brian Kopec (University of Kansas)
P49	The Intranasal Pathway for Non-invasive Delivery of Antibody Based Therapeutics to the Central Nervous System: Investigating Mechanism, Distribution and Dose Response Niyanta Kumar (University of Wisconsin-Madison)
P51	Effects of Glycogen Synthase Kinase 3 beta (GSK3 β) Inhibition on P-glycoprotein Expression and Activity in Cell Culture Models of the Blood-Brain Barrier Marlyn Laksitorini (University of Manitoba)
P53	pH Sensitive Liposomes for Vaccine or Chemotherapeutic Delivery Keeho (Arnold) Lee (University of Otago)
P65	Enhancing Immunological Response Towards Shigella spp. Through a Multivalent Subunit Vaccine Ryan Moulder (University of Kansas)
P67	No Touching! Abrasion of Adsorbed Protein is the Root Cause of Sub-Visible Particle Formation during Stirring Reza Nejadnik (Leiden University)
P69	Eliciting Adoptive Immune Responses Against Melanoma Using PEGylated Tumor Cell Membrane Vesicles Lukasz Ochyl (University of Michigan, Ann Arbor)
P71	Probing the Kinetic Stability of Tetanus Neurotoxin Using Label-free Biolayer Interferometry Pierce O'Neil (University of Kansas)
P73	Novel Antigen-Specific Immunotherapies for the Treatment of Autoimmune Disorders Chad Pickens (University of Kansas)
P85	Characterization of Site-specific N-glycosylation on IgG3 and Its Role in Interaction with Fc Receptors and Physical Stability Ishan Shah (University of Kansas)

P87	Effects of Transmembrane Domain Single-nucleotide Polymorphisms on the Breast Cancer Resistance Protein Noora Sjöstedt (University of Helsinki)
P89	Structural Transition of Copaxone® During Simulated Subcutaneous Injection Jimmy Song (University of Kansas)
P91	The Screening of Oil for Naproxen Microemulsion Jeon Sung-Hoon (Chungnam National University)
P101	Development and evaluation of virus-like particle vaccines against ricin Yangjie Wei (University of Kansas)

Thursday, November 10th 2:20 pm–3:20 pm

P13	Carnosine Decreases Nitric Oxide Concentrations and Modulates Activation and Differentiation in Stimulated Macrophages Through a Complex Biochemical Mechanism Giuseppe Caruso (University of Kansas)
P15	Polymeric Nano-shielding of Non-Human Primate Pancreatic Islets for Better Transplantation Outcome Seongwook Lee (Seoul National University)
P17	Saquinavir Loaded Acetalated Dextran Microconfetti – a Long Acting Protease Inhibitor Injectable Michael Collier (University of North Carolina)
P19	Proteomic Analysis of the Human Apical Sodium-dependent Bile Acid Transporter (ASBT; SLC10A2) Lindsay Czuba (University of Maryland, Baltimore)
P21	Influence of Humidity on the Mechanical Properties of Soluplus® and PVP Jiangnan Dun (University of Minnesota-Twin Cities)
P23	Mechanism-based Selection of Stabilization Strategy for Amorphous Formulation Khadijah Edueng (Uppsala University)
P35	Using Biophysical Techniques and Hydrogen Exchange to Evaluate Excipient Effects on Reversible Self-association, Phase Separation, and Solution Properties of Monoclonal Antibodies Yue Hu (University of Kansas)
P37	In vitro Drug Release Testing of Liposomal Temoporfin Formulations with the Dispersion Releaser Technology Laura Jablonka (Goethe University)
P39	The Influence of the Blending Method on Lactose Carrier Surface Modification with Magnesium Stearate on Fluticasone Dry Powder Inhaler Martin Jetzer (University of Basel)
P41	Chemical Stability of Different IgG4 Fc Glycoforms as a Model for Biosimilar Comparability Analysis Huan Kang (University of Kansas)
P43	Synthetic Lipoglycoconjugate Vaccines Against Group A Streptococcus Farjana Khatun (The University of Queensland)
P55	Novel Chemical Probes and Therapeutics for Autoimmune Disorders Martin Leon (University of Kansas)
P57	Structure, Preparation and Physicochemical Properties of Boronate Esters of 4-Methoxybenzene Boronic Acid and D-Mannitol Antonio Lopalco (University of Kansas)
P59	Development and Validation of a Platform to Determine Amorphous Solubility and Characterize Liquid-liquid Phase Separation Behavior Michaela McNiff (University of Kansas)
P61	Investigation of Mixing and Segregation of Ordered Mixtures for Dry Powder Inhaler Formulations Bruna Minatovicz (University of Connecticut)
P63	Synthesis and Evaluation of Multi-antigen I-Domain Conjugate (IDAC-6) Against Antigenic Spreading in Animal Models for Multiple Sclerosis Mario Edgar Moral (University of Kansas)
P75	Active Efflux and Brain Delivery of Novel pan-RAF Inhibitors Gautham Gampa (University of Minnesota)
P77	QSPR-model for Conjunctival Drug Permeability Eva Ramsay (University of Eastern Finland)
P79	Purification and Crystal Screening of the Topo II Interacting Region of Tumor Suppressor Adenomatous Polyposis Coli Aaron Rudeen (University of Kansas)

P81	Understanding Role of Drug-Polymer Interactions and Its Implications on the Blend Scale Homogeneity in Amorphous Solid Dispersions Using Solid-State NMR Spectroscopy Kanika Sarpal (University of Kentucky)
P83	Prediction of the Nasal and Plasma Pharmacokinetics of Locally-acting Nasal Drug Products Using a Semi-mechanistic Modeling Approach Uta Schilling (University of Florida)
P93	Systematic Determination of the Impact of Lipophilicity and Hydrogen Bond Formation on the Membrane Permeability of Small-molecule Drugs Ursula Thormann (Uppsala University)
P95	Improving Brain Delivery of a Peptide via BBB Modulation and Detection Using LC-MS-MS Kavisha Ulapane (University of Kansas)
P97	Oxidation of Rat Growth Hormone and a Semi-Physiologically Based Pharmacokinetic Model of Its Proteolysis After Subcutaneous Injection Ninad Varkhede (University of Kansas)
P99	In silico Workflow to Analyze the Thermostability of Monoclonal Antibody Domains Newton Wahome (University of Colorado, Denver)
103	Ultrasound Triggered Growth Factor Release – A New Approach in Bone Diseases Matthias Wojcik (University of Marburg)
105	Development of a Robust Method for the Characterization of Antibody Carbonylation Yi Yang (University of Kansas/Genentech)

Friday, November 11th 9:40 am–10:40 am

P2	Determination and Evaluation of Aerodynamic Parameters of Ciprofloxacin and Mucolytic Containing Dry Powder Inhalers Yagmur Akdag Cayli (Hacettepe University)
P4	B-cell Epitope Mapping of RiVax, a Candidate Ricin Vaccine Antigen Using Hydrogen Exchange-mass Spectrometry Sivakrishna Angalakurthi (University of Kansas)
P6	Future Manufacturing of Flexible Dosage Forms Lærke Arnfast (University of Copenhagen)
P8	Peptide Linkers with Differential Rates of Cargo Release in Human ARPE-19 Cells: A Strategy for Controlled Intracellular Drug Release Madhushree Bhattacharya (University of Helsinki)
P10	Meta-analysis of Hepatic Clearance Predictions from in Vitro-in Vivo Extrapolation Christine Bowman (University of California, San Francisco)
P12	Transition Metal Complexes as Potential Therapeutic Agents in Chagas Diseases Zumira Carneiro (Universidade de São Paulo)
P26	Pharmacokinetics and Biodistribution of a Novel Nanoemulsion Containing a Small Molecule drug for the Treatment of Lupus Nephritis Uma Fogueri (University of Colorado)
P28	Tailoring Valency and Peptide Prevalence in Soluble Antigen Arrays for Optimized Interruption of the Immunological Synapse J. Daniel Griffin (University of Kansas)
P30	Induced Neural Stem Cells as a Drug Delivery Platform for Glioblastoma Shaye Hagler (University of North Carolina)
P32	Photochemical Formation of Novel Cross-links between Cys and Ser Residues in Model Peptides Containing Disulfides: A Role for Thiyl Radicals Asha Hewardathna (University of Kansas)
P34	Design, Synthesis and Evaluation of Nanoparticle Diagnostics for Applications in Medical Imaging Nicholas Hobson (UCL School of Pharmacy)
P46	Physicochemical and Biological Characterization of Crofelemer for Identification of Critical Quality Attributes Using a Machine Learning Approach Peter Kleindl (University of Kansas)
P48	Complementary Particle and Biophysical Techniques for Evaluating Biosimilarity Aaron Krueger (University of Colorado School of Pharmacy)
P50	Identification of Blood-brain Barrier Membrane Protein Interacting with Exosome Derived from Breast Cancer Cell Line (MCF-7) in Human Hiroki Kuroda (Tohoku University)
P52	Characterizing Antigen-adjuvant Interactions Using Novel Spectroscopic Techniques Nicholas Larson (University of Kansas)

P54	Light-induced Protein Crosslink, Structure-related Reactivity and Stability During Frozen Storage: A Case Study Using rhDNase Ming Lei (Genentech)
P66	Attenuation of Endotoxin-induced Fever in Prostaglandin Transporter OATP2A1 Global and Macrophage-specific Knockout Mice Yoshinobu Nakamura (Kanazawa University)
P68	The Stress Buffering Roles of the UPR- implications to Cancer Immunotherapy Akram Obiedat (The Hebrew University of Jerusalem)
P70	Characterization of IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis Solomon Okbazghi (University of Kansas)
P72	The Use of GroEL-BLI Biosensor to Rapidly Assess “Pre-Aggregate” Populations for Monoclonal Antibodies of Different Stabilities Samantha Pace (University of Kansas)
P74	Sulfur-radical Cation Intermediate Leads to Hydrolysis and Oxidation of Methionine-Histidine Containing Proteins and Peptides Indira Prajapati (University of Kansas)
P86	Method Development for Quantifying Methionine Oxidation in a gp120 HIV Envelope Protein Josh Shipman (University of Kansas)
P88	Studies on the Microemulsion with Hydrophilic Hydroxycitric Acid and Lipophilic Conjugated Linoleic Acid Gi Ho Son (Chungnam National University)
P90	Differential Photosensitivity of Monoclonal Antibody Solutions with Salts Natalia Subelzu (University of Kansas)
P92	Quantitative Analysis of Intestinal Absorption and Metabolism of Benazepril in Rat Intestinal Single-pass Perfusion Experiment Shota Tabata (Kumamoto university)
P102	Gelatin Nanocarriers Stabilized by Incorporation in PLGA for the Delivery of Hydrophilic Macromolecules Agnes-Valencia Weiß (Saarland University)
P104	A Bifunctional Peptide Inhibitor – IgG1 Fc Fusion Suppresses Experimental Autoimmune Encephalomyelitis Derek White (University of Kansas)
P106	Interactions of HIV Drugs and Non-ionic (POE-PPO-PEO) Poloxamers at Molten States Enable Formation of Anti-HIV Protease Drug Particles for Injection Jesse Yu (University of Washington)

Friday, November 11th 3:10 pm – 4:10 pm

P14	Developing Novel Antibody-Drug Conjugates for Targeted Cancer Therapy Jingwen Chen (University of Southern California, School of Pharmacy)
P16	Antigen-Drug Conjugates as Antigen-Specific Immunotherapies in the Treatment of Autoimmune Diseases Matthew Christopher (University of Kansas)
P18	Gadolinium Deposition and C2E2: An Orally Bioavailable Chelating Agent for Prevention of Gd Retention After MRI Contrast Administration Carla Coste Sanchez (University of North Carolina - Chapel Hill)
P20	Targeted Proteomic Analysis of Cytochrome P450 Enzymes in Exosomes Secreted by HepG2 Cells after Induction with β - Naphthoflavone Laura Drbohlav (University of Kansas)
P22	Curcumin Loaded Photosensitive Lipopolyplexes for Enhanced Gene Delivery in Ovarian Carcinoma Cells Lili Duse (University of Marburg)
P24	Intranasal Delivery of Silver to Treat Acute Bacterial Rhinosinusitis in Mice Jonathan Falconer (University of Utah)
P36	Conjugating Hyaluronic Acid to Toll-like Receptor Agonists for the Development of New Vaccine Adjuvants Jordan Hunt (University of Kansas)
P38	Preformulation and In Vitro Characterization of Three Different Drugs-loaded eEmulsion: Fenofibrate, Ketoprofen, and Albendazole Woo Suk Jang (Chungnam National University)
P40	Sulfated Polysaccharide of Sepiella Maindroni Ink Inhibits MMP-2 Expression Through EGFR-mediated PI3K-Akt-mTOR and p38 MAPK Signaling Pathways Wenjie Jiang (Shandong University)
P42	Lipid Based Formulations Can Be Used to Control the Solid State Form of Poorly-water Soluble Ionisable Drugs Upon Precipitation During In-vitro Digestion Jamal Khan (Monash Institute of Pharmaceutical Sciences)

P44	Preparation and Characterization of Cationic Proliposome Prepared with Water-insoluble Chitosan to Enhance the Cellular Uptake of Protein Drug Tae-Hyeon Kim (Chungnam National University)
P56	Reduction Sensitive Nanogels as Antitumor Vaccine Delivery Systems Dandan Li (Utrecht University)
P58	Dry Coating a Cohesive Pharmaceutical Powder via High-shear Processing to Improve Powder Flowability Sharad Mangal (Purdue University)
P60	Starch-chitosan Polyplexes as a Novel, Versatile Drug Carrier System for Transfollicular Vaccination Hanzey Yasar (Saarland university)
P62	Elucidation of Factors Determining the Cell Distribution in Artificially Fabricated Mixed Multicellular Spheroids for Improved Insulin Secretion Yuya Mizukami (Kyoto University)
P64	Correlating the Impact of Different Well-defined Oligosaccharide Structures on Physical Stability Profiles of IgG1-Fc Glycoforms Apurva More (University of Kansas)
P76	Development of a HepaRG Cell-based Liver-on-a-Chip Microfluidic System Xiazi Qiu (University of Kansas)
P78	Fragmentation of Therapeutic Proteins by Soluble Tungsten Species Hasitha Rathnayaka (University of Kansas)
P80	Macrophage Depletion Reveals an Active Role of the Immune System in Determining the In Vivo Disposition of an Orally-bioavailable Drug Phillip Rzczycki (University of Michigan)
P82	In Vivo Discovery of Blood-brain Barrier Permeable Endogenous Protein Candidates Based on Comprehensive and Quantitative Data Independent Acquisition Proteomics Kazuki Sato (Tohoku University)
P84	Antibacterial Modification of Catheter Surfaces Utilizing PLGA-nanoparticles and Tetraether-DPPC-liposomes Benjamin Seitz (University of Marburg)
P94	Structural Characterization, Physicochemical Stability and Preformulation/formulation Development of a Double Mutant Heat Labile Toxin (dmLT) Protein Adjuvant Vishal Toprani (University of Kansas)
P96	Investigating the Link Between Gastric Motility and Distribution of an Orally Administered Drug in the Stomach of Fasted Healthy Volunteers Jens Van Den Abeele (KU Leuven)
P98	Organic Cation Transporter Interactions with Methamphetamine and Major Metabolites David Wagner (University of Washington)
P100	Local Delivery of Stem Cell Derived Secretome with Injectable Hydrogels for Myocardial Therapy Renaë Waters (University of Kansas)

TRANSPORTATION AND EMERGENCY INFORMATION

GPEN2016 Venue Addresses

The Eldridge Hotel (785) 749-5011
701 Massachusetts St.

Liberty Hall (785) 749-1972
644 Massachusetts St.

Lawrence Arts Center (785) 843-2787
940 New Hampshire St

Maceli's Banquet Hall (785) 331-2096
1031 New Hampshire St.

Circle S Ranch (785) 843-4124
3325 Circle S Ln.

Abe and Jake's Landing (785) 841-5855
8 East 6th Street

School of Pharmacy Building (785) 864-3591
2010 Becker Dr.

Hotel Addresses

Best Western (785)-843-9100
2309 Iowa St.

The Oread Hotel (785)-843-1200
1200 Oread Ave

The Eldridge Hotel (785)-749-5011
701 Massachusetts St.

Double Tree Hotel (785)-841-4994
2300 W. 6th St

TownePlace Suites Lawrence Downtown
(785)-842-8800
900 New Hampshire St.

SpringHill Suites (785)841-2700
1 Riverfront Plaza

Emergency Contact Information

The emergency number in Kansas is 911

Lawrence Memorial Hospital (785)-505-5000
325 Maine St.

GPEN2016 Organizing Committee Contact

GPEN2016@gmail.com

Transportation Details for Participants Staying in DOWNTOWN HOTELS

(The Oread, The Eldridge, Marriott SpringHill Suites or Marriott TownePlace Suites)

Thursday, November 10th:

- 5:45 pm Buses leave Lawrence Arts Center for the Circle S Ranch
- 8:30–9:30 pm From Circle S Ranch to Lawrence Arts Center

Saturday, November 12th:

- 8:00 am From your hotel to KU School of Pharmacy
 - Those staying at **The Eldridge and Oread** should use the bus leaving from the SpringHill Suites
 - Bus from SpringHill will be **outside** hotel on 6th Street
 - Bus from TownePlace Suites will be directly outside hotel

Transportation Details for Participants Staying at DOUBLETREE OR BEST WESTERN HOTELS

Wednesday, November 9th

- 3:00 pm From your hotel to The Eldridge Hotel
- 8:00 pm From The Eldridge Hotel to your hotel

Thursday, November 10th

- 7:15 am From your hotel to Lawrence Arts Center
- 4:20 pm From Lawrence Arts Center to your hotel
- 5:45 pm From your hotel to Circle S Ranch
- 8:30-9:30 pm From Circle S Ranch to your hotel

Friday, November 11th

- 7:30 am From your hotel to Lawrence Arts Center
- 5:10 pm From Lawrence Arts Center to your hotel
- 6:00 pm From your hotel to Abe & Jake's
- 9:00 pm From Abe and Jake's to your hotel

Saturday, November 12th

- 8:00 am From your hotel to KU School of Pharmacy

Transportation to Kansas City Airport

Friday, November 11th

- 5:15pm From Lawrence Arts Center
 - Only available for those with flights before 11:00am on 11/12

Saturday, November 12th

- Buses from School of Pharmacy depart at:
8:30am, 10:30am, 12:30pm, 2:30pm

Alternative Transportation

5 Guys Transportation (Airport): (816)-891-9999
Uber is available in Lawrence using the Uber app on smartphones

SPONSORS

The GPEN2016 Organizing Committee would like to thank all the GPEN2016 sponsors for their contribution and support that make this meeting possible.

PLATINUM SPONSORS

- ❖ Absorption Systems LP
- ❖ Genentech, Inc.
- ❖ The University of Kansas School of Pharmacy and Department of Pharmaceutical Chemistry

GOLD SPONSORS

- ❖ Abbvie
- ❖ Allergan, Plc.
- ❖ Bristol-Myers Squibb Co.
- ❖ City of Lawrence
- ❖ Eli Lilly and Company
- ❖ Gilead Sciences, Inc.
- ❖ Pfizer, Inc.

SILVER SPONSORS

- ❖ Amgen
- ❖ Bioscience and Technology Business Center, Inc.
- ❖ Boehringer-Ingelheim Pharmaceuticals, Inc.
- ❖ Ronald T. and Pamela K. Borchardt
- ❖ Cardinal Health Regulatory Sciences
- ❖ GlaxoSmithKline
- ❖ F. Hoffmann-La Roche AG
- ❖ The Nagai Foundation Tokyo
- ❖ Silvergate Pharmaceuticals, Inc.
- ❖ Stason Pharmaceuticals, Inc.
- ❖ Dhiren and Kailas Thakker

BRONZE SPONSORS

- ❖ American Association of Pharmaceutical Scientists
- ❖ AstraZeneca
- ❖ Ligand Pharmaceuticals
- ❖ Merck
- ❖ Novo Nordisk A/S
- ❖ Promius Pharma, LLC
- ❖ Sanofi

SUPPORTERS

- ❖ Molecular Pharmaceutics
- ❖ Celgene Corporation
- ❖ Elsevier
- ❖ Sofinnova Ventures

FRIENDS OF GPEN2016

- ❖ ACS Infectious Diseases
- ❖ Journal of Medicinal Chemistry
- ❖ ACS Medicinal Chemistry Letters
- ❖ APhA Journal of Pharmaceutical Sciences
- ❖ Forum for Pharmaceutical Technology Innovation, Japan
- ❖ KU Innovation & Collaboration
- ❖ Teikoku Seiyaku Co. Ltd.


“Without continual growth and progress, such words as improvement, achievement, and success have no meaning.”

“It takes many good deeds to build a good reputation, and only one bad one to lose it.”

“Tell me and I forget. Teach me and I remember. Involve me and I learn.”

“Wine is constant proof that God loves us and loves to see us happy.”

“We are all born ignorant, but one must work hard to remain stupid.”



BENJAMIN FRANKLIN

As a proud sponsor of GPEN,
we hope each and every attendee is committed to
improving pharmaceutical research by taking risks
and challenging the status quo.



**ABSORPTION
SYSTEMS®**

www.absorption.com

TRANSFORMING
IDEAS
INTO
COMMERCE

Facilities
Guidance
Connections

**BIOSCIENCE & TECHNOLOGY
BUSINESS CENTER**

AT THE
UNIVERSITY
OF KANSAS


Transforming Ideas Into Commerce

785.832-2110 Learn more at btbcku.com

AMGEN[®]

Pioneering science delivers vital medicines[™]

*Transforming the language
of life into vital medicines*



At Amgen, we believe that the answers to medicine's most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness – to dramatically improve their lives.

For more information about Amgen, our pioneering science and our vital medicines, visit www.amgen.com

Amgen is proud to support GPN2016

©2016 Amgen Inc. All rights reserved.



*Extraordinary medicine
requires extraordinary science.*

At Roche, we are committed to both. Discovering and developing innovative medicines and diagnostic tests to help people live better, longer lives.



Developing Products. Building Partnerships.

www.stasonpharma.com

abbvie

SOLVING THE WORLD'S TOUGHEST HEALTH CHALLENGES TAKES ALL OF US.

We start with research and innovation to develop and deliver new treatments to manage difficult diseases. As a global biopharmaceutical company, we build a pipeline of solutions—and work with peers, physicians, governments, and advocacy groups to make them available to patients and the healthcare systems which serve them.

Learn more at abbvie.com

PEOPLE. PASSION. POSSIBILITIES.



Many Paths. One Goal.™

discover your path now ▶



A World of Opportunities

At Pfizer we're committed to creating an environment where our colleagues can achieve success while contributing to the improved health of the world. We walk in as scientists, managers, as manufacturers. We're senior executives and recent graduates. But no matter where we come from or where we take our careers, we share a common purpose. To make the world a healthier place.

Right now, we are seeking to fill positions in every area of our business in all areas of the world. As a global company with resources dedicated to developing a myriad of medicines that span a wide range of health issues, we offer opportunities across our healthcare business units, as well as our internal and external divisions.

Discover your path. Apply now.

Visit www.pfizercareers.com to learn more about our business, our science and our commitment to global health.



www.pfizercareers.com

A woman with long brown hair, wearing a purple cardigan over a white floral shirt, blue jeans, and blue gardening gloves, sits on a stone ledge in a garden. She is holding a trowel and looking off to the side with a thoughtful expression. The background is filled with tall grasses and yellow flowers.

IT'S THE
EVERYDAY
THAT CHANGES
EVERYTHING


We believe in more than the big breakthroughs. And more than the next big thing.

We believe in the day-in day-out work of making science happen. And the millions of little victories — and failures — in between the breakthroughs. Because to us, it's the daily effort of everyday people that changes the future. So we don't stop. We keep working. Every day.

Genentech
A Member of the Roche Group

Jacki, patient

**Nurturing innovative ideas today
for more health tomorrow.**



Boehringer Ingelheim ranks among the world's 20 leading pharmaceutical corporations. Our vision drives us forward. It helps us to foster value through innovation in our company and to look to the future with constantly renewed commitment and ambition.

Visit us online at
us.boehringer-ingenelheim.com



Silvergate
Pharmaceuticals Inc.

Delivering high-quality medications
developed specifically for pediatric patients

www.silvergatepharma.com



Your product is the promise.

We give it wings.

You've worked tirelessly to develop a product with the power to change lives. Now it's time to create your strategy for gaining approval from regulatory health authorities.

At Cardinal Health Regulatory Sciences, our expert problem solvers offer the regulatory guidance needed to help you reduce risk during development, accelerate approval and maximize success.

Learn how we can create opportunities for you.
cardinalhealth.com/regulatorysciences



© 2016 Cardinal Health. All rights reserved. CARDINAL HEALTH, the Cardinal Health LOGO and ESSENTIAL TO CARE are trademarks or registered trademarks of Cardinal Health. All other marks are the property of their respective owners. Lit. No. 15R16-548043 (08/2016)

gsk do more
feel better
live longer

**A global healthcare
company on a mission**

We are a science-led global healthcare company – with three world-leading businesses – that researches, develops and manufactures innovative pharmaceutical medicines, vaccines and consumer healthcare products.

We are committed to widening access to our products, so more people can benefit, no matter where they live in the world or what they can afford to pay.





**FOR US, IT'S PRIDE
IN KNOWING WHAT
WE DO MATTERS**



GILEAD

Advancing Therapeutics.
Improving Lives.

Gilead Sciences, Inc. is a research-based biopharmaceutical company founded in 1987. Together we deliver life-saving therapies to patients in need. With the commitment and drive you bring to the workplace every day, you will be part of a team that is changing the world and helping millions of people live healthier, more fulfilling lives. Our worldwide staff of nearly 8,300 people is a close community where you can see the tangible results of your contributions, where every individual matters, and everyone has a chance to enhance their skills through ongoing development. Our scientific focus has resulted in 23 marketed products that are benefitting hundreds of thousands of people, a pipeline of late-stage drug candidates and unmatched patient access programs to ensure medications are available to those who could otherwise not afford them. By joining Gilead, you will further our mission to address unmet medical needs and improve life by advancing the care of patients with life-threatening diseases. For more details, go to: www.gilead.com/about

As an equal opportunity employer, Gilead Sciences Inc. is committed to a diverse workforce. In order to ensure reasonable accommodation for individuals protected by Section 503 of the Rehabilitation Act of 1973, the Vietnam Era Veterans' Readjustment Act of 1974, and Title I of the Americans with Disabilities Act of 1990, applicants who require accommodation in the job application process may contact careers@gilead.com for assistance.

Join our Talent Community:
<https://gilead.avature.net/Gilead>

Please apply at
www.gilead.com/careers

We Discover, Develop
and Commercialize Therapeutics
to Advance Patient Care.



ALLERGAN
IS PROUD TO SPONSOR
GPEN 2016

*Caitlin Sandahl, Allergan employee.
Account Specialist.*


We are a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Our worldclass team develops, manufactures and commercializes innovative branded pharmaceuticals and biologic products for patients around the world.

We are one team of dedicated employees, carving new paths, taking bold, decisive actions to deliver results and better outcomes for patients and providers.

For open positions please visit www.Allergan.com  **Allergan**



At Bristol-Myers Squibb, we are working together for patients. Our mission is clear—we discover, develop and deliver innovative medicines that help people prevail over serious diseases. And our sense of urgency is real—we work every day in every part of our company to make a meaningful difference in the lives of patients. It's what we do. It's why we do it.



Bristol-Myers Squibb

www.bms.com

© 2016 Bristol-Myers Squibb Company



“Diversity fosters creativity. Creativity drives innovation. And innovation ultimately leads to business success.”

John Lechleiter, Ph.D., Chairman, President and CEO

Lilly celebrates 140 years. To learn more, visit www.lillyforbetter.com.

2016 CA Approved for External Use PRINTED IN USA ©2016, Eli Lilly and Company. ALL RIGHTS RESERVED.



ACADEMIC PARTICIPANTS

First Name	Last Name	University	Email	Poster or Podia
Sanjeev	Agarwal	University of Kansas	sanjeev.agarwal@ku.edu	P1
Yagmur	Akdag Cayli	Hacettepe University	ymr.akdag@gmail.com	P2
Abdullah	Al-Hossaini	University of Kansas	ama@ku.edu	P3
Khalid	Al-Kinani	University of Kansas	khalid81@ku.edu	S12
Parthiban	Anbalagan	National University of Singapore	a0052132@u.nus.edu	S67
Brad	Anderson	University of Kentucky	bande2@email.uky.edu	
Sivakrishna	Angalakurthi	University of Kansas	s214a774@ku.edu	P4
Lorena	Antunez Napolitano	University of Kansas	lorenarantunez@gmail.com	P5
Lærke	Arnfast	University of Copenhagen	laerke.arnfast@sund.ku.dk	P6
Per	Artursson	Uppsala University	per.artursson@farmaci.uu.se	
Kenneth	Audus	University of Kansas	audus@ku.edu	
Patrick	Augustijns	KU Leuven	patrick.augustijns@kuleuven.be	
Joseph	Balthasar	University at Buffalo, SUNY	jb@buffalo.edu	S34, S38
Philippe	Berben	KU Leuven	philippe.berben@kuleuven.be	P7
Christel	Bergström	Uppsala University	christel.bergstrom@farmaci.uu.se	S68
Cory	Berkland	University of Kansas	berkland@ku.edu	S55
Madhushree	Bhattacharya	University of Helsinki	madhushree.bhattacharya@helsinki.fi	P8
Rupesh	Bommana	University of Kansas	r224b709@ku.edu	P9
Gerrit	Borchard	University of Geneva	gerrit.borchard@unige.ch	S60
Pamela K.	Borchardt	University of Kansas	pamborchardt@hotmail.com	
Ronald T.	Borchardt	University of Kansas	rborchardt@ku.edu	
Christine	Bowman	University of California, San Francisco	christine.bowman@ucsf.edu	P10
Davide	Brambilla	ETH Zurich	davide.brambilla@pharma.ethz.ch	S59
Birger	Brodin	University of Copenhagen	birger.brodin@sund.ku.dk	
Kim	Brouwer	University of North Carolina	kbrouwer@unc.edu	
Youngro	Byun	Seoul National University	yrbyun@snu.ac.kr	
Enyuan	Cao	Monash University	enyuan.cao@monash.edu	P11
Zumira	Carneiro	University of São Paulo	azumira@hotmail.com	P12
Giuseppe	Caruso	University of Kansas	gcaruso@ku.edu	P13
Igor	Chekhtman	Monash University	igor.chekhtman@monash.edu	S17
Jingwen	Chen	University of Southern California	jingwenc@usc.edu	P14
Mingnan	Chen	University of Utah	mingnan.chen@utah.edu	
Eng Hui	Chew	National University of Singapore	phaceh@nus.edu.sg	
Cheong-Weon	Cho	Chungnam National University	chocw@cnu.ac.kr	
Jeong Uk	Choi	Seoul National University	jwseries@gmail.com	S79
Matthew	Christopher	University of Kansas	m905c980@ku.edu	P16
Michael	Collier	University of North Carolina	mcollicie@email.unc.edu	P17
Martin	Conda-Sheridan	University of Nebraska Medical Center	martin.condasheridan@unmc.edu	
Carla	Coste Sanchez	University of North Carolina	carlacs@email.unc.edu	P18
Christopher	Cunningham	University Wisconsin- Madison	chris.cunningham@cuw.edu	
Lindsay	Czuba	University of Maryland, Baltimore	lcczuba@umaryland.edu	P19
Sérgio	de Albuquerque	University of São Paulo	sdalbuqu@fcfrp.usp.br	
Amelia	Deitchman	University of Florida	andeitchman@ufl.edu	S33
Brandon	DeKosky	University of Kansas	bdekosky@gmail.com	

Tahnee	Dening	University of South Australia	tahnee.dening@mymail.unisa.edu.au	S25
Hartmut	Derendorf	University of Florida	hartmut@ufl.edu	
Tiziana	Di Francesco	University of Geneva	tiziana.difrancesco@unige.ch	S31
Aaron	Dolor	University of California, San Francisco	aaron.dolor@ucsf.edu	S3
Laura	Drbohlav	University of Kansas	drbohlav@ku.edu	P20
Jiangnan	Dun	University of Minnesota	dunxx004@umn.edu	P21
Lili	Duse	University of Marburg	lili.duse@pharmazie.uni-marburg.de	P22
Khadijah	Edueng	Uppsala University	khadijah.edueng@farmaci.uu.se	P23
William	Elmquist	University of Minnesota	elmqu011@umn.edu	
Sara	Eyal	Hebrew University of Jerusalem	sarae@ekmd.huji.ac.il	
Ahmed	Fahad	University of Kansas	ahmed.fahad@ku.edu	
Vincent	Faivre	Institut Galien Paris-Sud	vincent.faivre@u-psud.fr	
Jonathan	Falconer	University of Utah	jonathan.falconer@utah.edu	P24
Mei	Feng	University of Kansas	meifeng@ku.edu	P25
Uma	Fogueri	University of Colorado	uma.fogueri@ucdenver.edu	P26
Laird	Forrest	University of Kansas	lforrest@ku.edu	S57
Adam	Friedman	University of North Carolina, Chapel Hill	friedmad@email.unc.edu	P27
Daichi	Fujita	Kanazawa University	fujita.d@stu.kanazawa-u.ac.jp	S24
Gutham	Gampa	University of Minnesota	gampa002@umn.edu	P75
Aditya	Gandhi	University of Colorado	aditya.gandhi@ucdenver.edu	S13
Morgan	Giles	University of Michigan	gilesm@umich.edu	S5
J. Daniel	Griffin	University of Kansas	jdgriffin@ku.edu	P28
Cen	Guo	University of North Carolina, Chapel Hill	ceng@email.unc.edu	S42
R. Neslihan	Gürsoy	Hacettepe University	ngursoy@hacettepe.edu.tr	
Shaye	Hagler	University of North Carolina, Chapel Hill	shagler@unc.edu	P30
Atsushi	Hamana	Kyoto University	hamana.atsushi.46c@st.kyoto-u.ac.jp	S49
Su Min	Han	Chungnam National University	sumni91@naver.com	S30
Brittany	Hartwell	University of Kansas	b703r792@ku.edu	P31
William	Hedrich	University of Maryland	whedrich@umaryland.edu	S44
Nancy	Helm	University of Kansas	nhelm@ku.edu	
Asha	Hewarathna	University of Kansas	asha@ku.edu	P32
Tze Ning	Hiew	National University of Singapore	tzening@u.nus.edu	P33
Paul	Ho	National University of Singapore	phahocl@nus.edu.sg	
Rodney	Ho	University of Washington	rodneyho@uw.edu	
Nicholas	Hobson	UCL School of Pharmacy	nicholas.hobson.12@ucl.ac.uk	P34
Nicholas	Hopper	Concordia University of Wisconsin	nicholas.hopper@cuw.edu	
Yutaro	Hoshi	Tohoku University	yhoshi@dc.tohoku.ac.jp	S35
Yue	Hu	University of Kansas	y163h421@ku.edu	P35
Jordan	Hunt	University of Kansas	jhunt676@gmail.com	P36
Teruko	Imai	Kumamoto University	iteruko@gpo.kumamoto-u.ac.jp	
Georgios	Imanidis	University of Basel	georgios.imanidis@unibas.ch	
Laura	Jablonka	Goethe University	jablonka@em.frankfurt.de	P37
Woo Suk	Jang	Chungnam National University	wsjang815@naver.com	P38
Martin	Jetzer	University of Basel	martin.jetzer@unibas.ch	P39
Wenjie	Jiang	Shandong University	jiangwenjie_123@126.com	P40
Wim	Jiskoot	Leiden University	w.jiskoot@lacdr.leidenuniv.nl	
Huan	Kang	University of Kansas	kanghuancpu@gmail.com	P41
Michael	Keusgen	University of Marburg	dekanat.pharmazie@staff.uni-marburg.de	

Jamal	Khan	Monash University	jamal.khan@monash.edu	P42
Farjana	Khatun	The University of Queensland	f.khatun@uq.edu.au	P43
Tae-Hyeon	Kim	Chungnam National University	mir1660@gmail.com	P44
Sarah	Kindgen	ETH Zurich	sarah.kindgen@pharma.ethz.ch	P45
Daniel	Kirby	Aston University	d.j.kirby1@aston.ac.uk	
Peter	Kleindl	University of Kansas	peterkleindl@gmail.com	P46
Gregory	Knipp	Purdue University	gknipp@purdue.edu	
Robbert	Kok	Utrecht University	r.j.kok@uu.nl	
Brian	Kopec	University of Kansas	brian.kopec@ku.edu	P47
Edmund	Kostewicz	Goethe University	kostewicz@em.uni-frankfurt.de	
Jake	Kraft	University of Washington	kraft@uw.edu	S61
Jeff	Krise	University of Kansas	krise@ku.edu	
Deanna	Kroetz	University of California, San Francisco	deanna.kroetz@ucsf.edu	
Aaron	Krueger	University of Colorado	aaron.krueger@ucdenver.edu	P48
Niyanta	Kumar	University of Wisconsin-Madison	niyanta.kumar@wisc.edu	P49
Hiroki	Kuroda	Tohoku University	hiroki.kuroda.p3@dc.tohoku.ac.jp	P50
Rukmini	Ladi	University of Kansas	rukminiladi@gmail.com	
Marlyn	Laksitorini	University of Manitoba	laksitorini@yahoo.com	P51
Nicholas	Larson	University of Kansas	nicholas.larson@ku.edu	P52
Monika	Lavan	Purdue University	mlavan@purdue.edu	S27
Buddhadev	Layek	University of Minnesota	blayek@umn.edu	S1
Seongwook	Lee	Seoul National University	seungwook7@hotmail.com	P15
Keeho (Arnold)	Lee	University of Otago	leeke297@student.otago.ac.nz	P53
Martin	Leon	University of Kansas	m0441877@ku.edu	P55
Mara	Leone	Leiden University	m.leone@lacdr.leidenuniv.nl	S76
Zhe	Li	University of Southern California	zli351@usc.edu	S51
Dandan	Li	Utrecht University	d.li@uu.nl	P56
Ryan	Lillico	University of Manitoba	umlillic@myumanitoba.ca	S10
Yan	Liu	Shandong University	lyly2222@126.com	S56
Antonio	Lopalco	University of Kansas	lopalco@ku.edu	P57
Ruolin	Lu	University of Kansas	Luxxx833@umn.edu	
Susan	Lunte	University of Kansas	slunte@ku.edu	
Donald	Mager	University at Buffalo, SUNY	dmager@buffalo.edu	S36
Krishna	Mallela	University of Colorado	krishna.mallela@ucdenver.edu	
Arushi	Manchanda	University Of Connecticut	arushi.manchanda@uconn.edu	S28
Sharad	Mangal	Purdue University	Sharad.mangal08@gmail.com	P58
Aniv	Mann	Hebrew University of Jerusalem	aniv.mnn@gmail.com	S11
Michaela	McNiff	University of Kansas	mmcniiff@ku.edu	P59
Sandro	Mecozzi	University of Wisconsin-Madison	sandro.mecozzi@wisc.edu	
Russ	Middaugh	University of Kansas	middaugh@ku.edu	S75
Elodie	Millart	Institut Galien Paris Sud	elodie.millart@u-psud.fr	S18
Don	Miller	University of Manitoba	donald.miller@umanitoba.ca	
Bruna	Minatovicz	University of Connecticut	bruna.minatovicz@uconn.edu	P61
Jaya	Mishra	University of Copenhagen	jaya.mishra@sund.ku.dk	S32
Yuya	Mizukami	Kyoto university	mizukami.yuuya.53w@st.kyoto-u.ac.jp	P62
Jukka	Monkkonen	University of Eastern Finland	jukka.monkkonen@uef.fi	
Mario Edgar	Moral	University of Kansas	mmoral@ku.edu	P63

Apurva	More	University of Kansas	apurvam@ku.edu	P64
Ryan	Moulder	University of Kansas	kmoulder@ku.edu	P65
Peter	Moyle	The University of Queensland	p.moyle@uq.edu.au	
Anette	Mullertz	University of Copenhagen	anette.mullertz@sund.ku.dk	
Yoshinobu	Nakamura	Kanazawa University	y.nakamura@stu.kanazawa-u.ac.jp	P66
Nantaporn	Namviriyachote	Chulalongkorn University	nantaporn.nam@gmail.com	S15
Reza	Nejadnik	Leiden University	m.r.nejadnik@lacdr.leidenuniv.nl	P67
Joe	Nicolazzo	Monash University	joseph.nicolazzo@monash.edu	
Lisa	Nothnagel	Goethe University, Frankfurt	nothnagel@em.uni-frankfurt.de	S58
Akram	Obiedat	Hebrew University of Jerusalem	akram.obiedat@mail.huji.ac.il	P68
Lukasz	Ochyl	University of Michigan	ochyl@umich.edu	P69
Solomon	Okbazghi	University of Kansas	solomonians@gmail.com	P70
Pierce	ONeil	University of Kansas Medical Center	poneil@kumc.edu	P71
Tetsuya	Ozeki	Nagoya City University	ozekit@phar.nagoya-cu.ac.jp	
Samantha	Pace	University of Kansas	kickitsoccer11@yahoo.com	P72
Jeong-Sook	Park	Chungnam National University	eicosa@cnu.ac.kr	
Laura	Pelkonen	University of Eastern Finland	laura.pelkonen@uef.fi	S23
Bjorn	Peters	University of Kansas	bjorn.peters@ku.edu	
Sam	Peterson	University of Kansas	sampeterson@ku.edu	
Thu	Pham	Aston University	phamt2@aston.ac.uk	S16
Chad	Pickens	University of Kansas	cpickens@ku.edu	P73
Wendy	Picking	University of Kansas	wendy.picking@ku.edu	S78
William	Picking	University of Kansas	picking@ku.edu	S77
Michael	Pikal	University of Connecticut	michael.pikal@uconn.edu	S53
Shashank Reddy	Pinnapireddy	University of Marburg	shashank.pinnapireddy@pharmazie.uni-marburg.de	S6
Indira	Prajapati	University of Kansas	i496p168@ku.edu	P74
Melissa	Pressnall	University of Kansas	pressnallm@ku.edu	
Xiazi	Qiu	University of Kansas	qiux@ku.edu	P76
Thomas	Rades	University of Copenhagen	thomas.rades@sund.ku.dk	
Eva	Ramsay	University of Eastern Finland	eva.ramsay@uef.fi	P77
Hasitha	Rathnayaka	University of Kansas	hasitha@ku.edu	P78
Anna-Kaisa	Rimpelä	University of Helsinki	anna-kaisa.rimpela@helsinki.fi	S22
Garnpimol	Ritthidej	Chulalongkorn University	garnpimol.c@chula.ac.th	
Nair	Rodriguez-Hornedo	University of Michigan	nrh@umich.edu	S70
Jari	Rubbens	KU Leuven	jari.rubbens@kuleuven.be	S47
Aaron	Rudeen	University of Kansas	Aaron.rudeen@gmail.com	P79
Marika	Ruponen	University of Eastern Finland	marika.ruponen@uef.fi	
Phillip	Rzeczycki	University of Michigan	pmrzec@umich.edu	P80
Adem	Sahin	Hacettepe University	ademsahin@outlook.com	S7
Kanika	Sarpal	University of Kentucky	kanika.sarpal@uky.edu	P81
Kazuki	Sato	Tohoku University	kazuki@dc.tohoku.ac.jp	P82
Nishant	Sawant	University of Kansas	nishant.sawant@ku.edu	
Uta	Schilling	University of Florida	uschilling@ufl.edu	P83
Christian	Schoneich	University of Kansas	schoneic@ku.edu	S50
Anna	Schwendeman	University of Michigan	annaschw@med.umich.edu	
Steven	Schwendeman	University of Michigan	schwende@umich.edu	
Benjamin	Seitz	University of Marburg	benjamin.seitz@pharmazie.uni-marburg.de	P84

Nico	Setiawan	University of Kentucky	nico.setiawan@uky.edu	S21
Dhaval	Shah	University at Buffalo, SUNY	dshah4@buffalo.edu	S39
Ishan	Shah	University of Kansas	ishanshah@ku.edu	P85
Josh	Shipman	University of Kansas	shipman@ku.edu	P86
Teruna	Siahaan	University of Kansas	siahaan@ku.edu	S43
Katerina	Simkova	University of Basel	katerina.simkova@unibas.ch	S26
Noora	Sjöstedt	University of Helsinki	noora.sjostedt@helsinki.fi	P87
Gi Ho	Son	Chungnam National University	kyk2576@naver.com	P88
Jimmy	Song	University of Kansas	jysong@ku.edu	P89
Valentino	Stella	University of Kansas	stella@ku.edu	
Jason	Stewart	University of Kansas	jason.stewart@ku.edu	
John	Stobaugh	University of Kansas	stobaugh@ku.edu	S52
Natalia	Subelzu	University of Kansas	nsubelzu@gmail.com	P90
Jeon	Sung-Hoon	Chungnam National University	ddoyfe@naver.com	P91
Peter	Swaan	University of Maryland	pswaan@rx.umaryland.edu	
Shota	Tabata	Kumamoto University	160y1004@st.kumamoto-u.ac.jp	P92
Yoshinobu	Takakura	Kyoto University	takakura@pharm.kyoto-u.ac.jp	
Ikumi	Tamai	Kanazawa University	tamai@p.kanazawa-u.ac.jp	
Sou	Tanoue	Kumamoto University	141y2003@st.kumamoto-u.ac.jp	S14
Rattavut	Teerakapibal	University of Wisconsin-Madison	teerakapibal@wisc.edu	S69
Tetsuya	Terasaki	Tohoku University	terasaki.tetsuya@m.tohoku.ac.jp	
Dhiren	Thakker	University of North Carolina	dhiren_thakker@unc.edu	
Ursula	Thormann	Uppsala University	ursula.thormann@farmaci.uu.se	P93
Carolin	Thum	Saarland University	carolin.thum@uni-saarland.de	S72
Peter	Tiefenböck	ETH Zurich	peter.tiefenboeck@pharma.ethz.ch	S40
Thomas	Tolbert	University of Kansas	tolbert@ku.edu	S48
Vishal	Toprani	University of Kansas	vishal.toprani@ku.edu	P94
Andrea	Treyer	Uppsala University	andrea.treyer@farmaci.uu.se	S19
Kavisha	Ulapane	University of Kansas	kavisha@ku.edu	P95
Arto	Urtti	University of Helsinki	arto.urtti@helsinki.fi	
Jens	Van Den Abeele	KU Leuven	jens.vandenabeele@kuleuven.be	P96
Ninad	Varkhede	University of Kansas	ninad.varkhede@ku.edu	P97
Jan-Jaap	Verhoef	Utrecht University	j.j.f.verhoef@uu.nl	S2
Elisabeth	Verpoorte	University of Groningen	E.M.J.Verpoorte@rug.nl	S45
David	Volkin	University of Kansas	volkin@ku.edu	S73
David	Wagner	University of Washington	davidwag@uw.edu	P98
Newton	Wahome	University of Colorado, Denver	newton.wahome@ucdenver.edu	P99
Greg	Walker	University of Otago	greg.walker@otago.ac.nz	
Yu	Wan	The University of Queensland	yu.wan@uqconnect.edu.au	S8
Fengshan	Wang	Shandong University	wangfanfan@sdu.edu.cn	
Michael Zhuo	Wang	University of Kansas	michael.wang@ku.edu	S46
Renaë	Waters	University of Kansas	renae.waters@gmail.com	P100
Jarod	Waybright	University of North Carolina	jarodw@unc.edu	S37
Laura	Weber	University of Nebraska Medical Center	laura.weber@unmc.edu	S54
Yangjie	Wei	University of Kansas	y874w268@ku.edu	P101
Agnes-Valencia	Weiß	Saarland University	agnes.weiss@uni-saarland.de	P102
Di	Wen	University of Nebraska Medical Center	diwen.nju@gmail.com	P103
Xian	Weng Jiang	UCL School of Pharmacy	x.weng.12@ucl.ac.uk	S29

Derek	White	University of Kansas	derek.white02@ku.edu	P104
Des	Williams	University of South Australia	des.williams@unisa.edu.au	
Matthias	Wojcik	University of Marburg	matthias.wojcik@pharmazie.uni-marburg.de	P105
Tehetina	Woldemichael	University of Michigan	wolte@umich.edu	P29
Yi	Yang	University of Kansas/Genentech	y784y493@ku.edu	P107
Sasi bhushan	Yarragudi	University of Otago	yarsa131@student.otago.ac.nz	S9
Hanzey	Yasar	Saarland University	hanzey.yasar@helmholtz-hzi.de	P60
Jesse	Yu	University of Washington	yuj73@uw.edu	P109
Yong	Zhang	University of Southern California	yongz@usc.edu	
Zhongxi	Zhao	Shandong University	zzzhao@sdu.edu.cn	
Peng	Zhao	University of Utah	zhaopeng.better@hotmail.com	S4
Tony	Zhou	Purdue University	tonyzhou@purdue.edu	

OTHER PARTICIPANTS

First Name	Last Name	Company	Email	Code
Susanna	Abrahmsén Alami	AstraZeneca	susanna.abrahmsen-alamia@astrazeneca.com	
Francisco	Alvarez	Amgen	fralvare@amgen.com	
Michael	Beckloff	Silvergate Pharmaceuticals, Inc.	michael.beckloff@silvergatepharma.com	
Thomas	Borchardt	AbbVie	thomas.borchardt@abbvie.com	
Shirlynn	Chen	Boehringer-Ingelheim Pharmaceuticals, Inc.	shirlynn.chen@boehringer-ingelheim.com	
Nik	Chetwyn	Genentech, Inc.	chetwyn.nik@gene.com	
Patrick	Dentinger	Absorption Systems LP	pdentinger@absorption.com	
Joern	Drustrup	Novo Nordisk A/S	jdr@novonordisk.com	
Dana	Filoti	AbbVie	dana.filoti@abbvie.com	
Michael	Hageman	Bristol-Myers Squibb Co.	michael.hageman@bms.com	S66
Ismael	Hidalgo	Absorption Systems LP	ihidalgo@absorption.com	S41
Al	Kearney	GlaxoSmithKline	Albert.S.Kearney@gsk.com	
Parag	Kolhe	Pfizer, Inc.	parag.kolhe@pfizer.com	
Frank	Kruse	Bioscience & Technology Business Center	frkruse@btbcku.com	
Ming	Lei	Genentech, Inc.	lei.ming@gene.com	P54
Bianca	Liederer	Genentech, Inc.	biancal@gene.com	
Joe	Lubach	Genentech, Inc.	lubach.joseph@gene.com	
Rao	Mantri	Bristol-Myers Squibb Co.	Rao.Mantri@bms.com	S71
Aaron	Markham	Eli Lilly and Company	markham_aaron@lilly.com	
Brian	Mattioni	Eli Lilly and Company	mattioni_brian_e@lilly.com	
Fred	Meyer	University of Kansas Medical Center	fmeyer@kumc.edu	
Robert	Mo	Pfizer, Inc.	robert.mo@pfizer.com	
Sesha	Neervannan	Allergan, Plc.	Neervannan_Sesha@allergan.com	
Franklin	Okumu	Promius Pharma, LLC	fokumu@drreddys.com	
Justin	Pennington	Merck	justin.pennington@merck.com	
Jeff	Peterson	Eli Lilly and Company	Pete@lilly.com	
James	Pipkin	Ligand Pharmaceuticals	jdpiipkin@ligand.com	
Maria	Posada	Eli Lilly and Company	mmposada@lilly.com	
Mike	Powell	Sofinnova Ventures	jenn@sofinnova.com	
Lichuan	Liu	Genentech, Inc.	Liu.lichuan@gene.com	
Janice	Silverman	American Chemical Society	j_silverman@acs.org	
Parag	Kolhe	Pfizer, Inc.	parag.kolhe@pfizer.com	
Livia	Sexton	University of Kansas Endowment	lsexton@kuendowment.edu	
Jay	Sisco	JM Sisco Pharma Consulting, LLC	jaysiscollc@aol.com	
Robert	Strickley	Gilead Sciences, Inc.	robert.strickley@gilead.com	
Monica	Tijerina	Gilead Sciences, Inc.	monica.tijerina@gilead.com	
Andy	Trammel	Cardinal Health Regulatory Sciences	andrew.trammel@cardinalhealth.com	
G.R.	Underwood	Bioscience & Technology Business Center	grunderwood@btbcku.com	
Suchitra	Venugopal	Sanofi	suchitra.venugopal@genzyme.com	
Diana	Wood	Stason Pharmaceuticals	Diana.wood@stasonpharma.com	

A warm welcome for all of you to attend GPEN2018 in Singapore



NUS

National University
of Singapore





• Kansas: The Sunflower State •